Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation

Vaccinex, Inc., a clinical-stage biotechnology company based in Rochester, New York, is grappling with a potential delisting from the Nasdaq Stock Market. The company revealed that it had failed to meet Nasdaq’s continued listing standards, specifically falling short of the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ […]

Leave a Reply

Your email address will not be published.

Previous post U.S. GoldMining Issues Year-End Letter to ShareholdersAnchorage, Alaska – December 17, 2024 – U.S. GoldMining Inc. (NASDAQ: USGO) (“U.S. GoldMining” or the “Company”) has recently provided a year-end update through a letter from its Chairman, Alastai
Next post TLGY Acquisition Corporation Extends Initial Business Combination Deadline